Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy
Small · 2023-06 · 19 (23)
DOI: 10.1002/smll.202206211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 08.03.2023. Verfasst von Qiuxia Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 391 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Cancer immunotherapy is a promising antitumor approach, whereas nontherapeutic side effects, tumor microenvironment (TME) intricacy, and low tumor immunogenicity limit its therapeutic efficacy. In recent years, combination immunotherapy with other therapies has been proven to considerably increase antitumor efficacy. However, achieving codelivery of the drugs to the tumor site remains a major challenge. Stimulus‐responsive nanodelivery systems show controlled drug delivery and precise drug release. Polysaccharides, a family of potential biomaterials, are widely used in the development of stimulus‐responsive nanomedicines due to their unique physicochemical properties, biocompatibility, and modifiability. Here, the antitumor activity of polysaccharides and several combined immunotherapy strategies (e.g., immunotherapy combined with chemotherapy, photodynamic therapy, or photothermal therapy) are summarized. More importantly, the recent progress of polysaccharide‐based stimulus‐responsive nanomedicines for combination cancer immunotherapy is discussed, with the focus on construction of nanomedicine, targeted delivery, drug release, and enhanced antitumor effects. Finally, the limitations and application prospects of this new field are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611130, China.
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
- School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, 999078, China.
ORCID-Profile: Xing Liu, Kaipei Luo
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Li, Q., Liu, X., Yan, C., Zhao, B., Zhao, Y., Yang, L., Shi, M., Yu, H., Li, X., & Luo, K. (2023). Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy. Small, 19(23). https://doi.org/10.1002/smll.202206211
Vancouver
Li Q, Liu X, Yan C, Zhao B, Zhao Y, Yang L, et al. Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy. Small. 2023;19(23). doi:10.1002/smll.202206211
BibTeX
@article{Li2023,
author = {Li, Qiuxia and Liu, Xing and Yan, Chunmei and Zhao, Bolin and Zhao, Yuxin and Yang, Lu and Shi, Mingyi and Yu, Hua and Li, Xiaofang and Luo, Kaipei},
title = {Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy},
journal = {Small},
year = {2023},
volume = {19},
number = {23},
doi = {10.1002/smll.202206211}
}
EUVIMED